Sharon Bio Medicine shares rise 9 percent
Bangalore: Sharon Bio Medicine stock was among the top gainers after its price went up by nearly 9 percent. After opening the day at 
130.70, the stock touched its 52 week high of 148.50, before closing trade at 135.05, with a gain of 8.96 percent. Through the day, 51918 Sharon Bio Medicine shares were traded in the market with the current P/E ratio of the stock at 11.06. The 52 week stock price chart is on the left.
Sharon Bio-Medicine is an India-based company. The Company operates in the pharmaceuticals/chemicals segment. As of June 30, 2009, it had developed a number of products in active pharmaceutical ingredient (API), intermediates and formulations. The Company's products include Glimpride, 4-Methoxy Benzyl Amine, Di Methyl Eac, Denmadol, Metroprolol, Ranitidine Hydrochloride and Shanafil. The Company's wholly owned subsidiary is Sharon International FZE, which is engaged in trading and marketing of pharmaceutical and other items.
During the fiscal year ended June 30, 2009, Stonewood Cem-Fab merged with the Company.
Currently, 5 analysts are following the stock, 3 out of them are recommending to buy the stock. The consensus recommendation is that the stock will outperform.
130.70, the stock touched its 52 week high of 148.50, before closing trade at 135.05, with a gain of 8.96 percent. Through the day, 51918 Sharon Bio Medicine shares were traded in the market with the current P/E ratio of the stock at 11.06. The 52 week stock price chart is on the left.
Sharon Bio-Medicine is an India-based company. The Company operates in the pharmaceuticals/chemicals segment. As of June 30, 2009, it had developed a number of products in active pharmaceutical ingredient (API), intermediates and formulations. The Company's products include Glimpride, 4-Methoxy Benzyl Amine, Di Methyl Eac, Denmadol, Metroprolol, Ranitidine Hydrochloride and Shanafil. The Company's wholly owned subsidiary is Sharon International FZE, which is engaged in trading and marketing of pharmaceutical and other items.
During the fiscal year ended June 30, 2009, Stonewood Cem-Fab merged with the Company.
Currently, 5 analysts are following the stock, 3 out of them are recommending to buy the stock. The consensus recommendation is that the stock will outperform.